Review of tenofovir-emtricitabine

References

• BarriosAGracia-BenayasTGonzalez-LahozJTenofovir-related nephrotoxicity in HIV-infected patientsAIDS200418960315060449
   PubMed Web of Science ®Google Scholar
• BarriosARendonANegredoEParadoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosineAIDS20051917223 AIDS, 19:569–75 Comment in16184059
   PubMed Web of Science ®Google Scholar
• BartlettJGGallantJE2005–2006 Medical management of HIV infection. Johns Hopkins Medicine. Health Publishing Business Group2005
   Google Scholar
• BenhamouYTreatment algorithm for chronic hepatitis B in HIV-infected patientsJ Hepatol2006441 SupplS90416352368
   PubMed Web of Science ®Google Scholar
• BenhamouYTubiaRThibaultVTenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virusNew Engl J Med2003348177812519935
   PubMed Web of Science ®Google Scholar
• BensonCAVan der HorstCLamarcaAA randomized study of emtricitabine and lamivudine in stably suppressed patients with HIVAIDS20041822697615577539
   PubMed Web of Science ®Google Scholar
• BessesenMIvesDCondreayLChronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudineClin Infect Dis1999281032510452630
   PubMed Web of Science ®Google Scholar
• CassettiIMadrugaJVRSuleimanJMAHThe safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 5 years in antiretroviral-naive patients20068th International Congress on Drug Therapy in HIV InfectionNovember 12–16Glasgow Abstract P152
   Google Scholar
• CassettiIMadrugaJVSuleimanJMThe safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patientsHIV Clin Trials200781647217621463
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services-Office of AIDS Advisory CouncilGuidelines for the use of antiretroviral agents for HIV-1 infected adults and adolescents20065Bethesda, MD Accessed September 25, 2006. URL: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• DoreGJCooperDAPozniakALEfficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients co-infected with HIV-1 and hepatitis B virusJ Infect Dis200418911859215031786
   PubMed Web of Science ®Google Scholar
• FramptonJEPerryCMEmtricitabine: a review of its use in the management of HIV infectionDrugs20056514274815977972
   PubMed Web of Science ®Google Scholar
• GallantJEDeJesusEArrasJRTenofovir DF, Emtricitabine, and Efavirenz vs Zidovudine, and Efavirenz for HIVN Engl J Med20063542516016421366
   PubMed Web of Science ®Google Scholar
• GallantJEStaszewskiSPozniakALEfficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trialJAMA200429219120115249568
   PubMed Web of Science ®Google Scholar
• GallantJPozniakAStaszewskiSEfficacy and Safety of Tenofo-vir-containing vs non-Tenofovir-containing Regimens in Black ART-naive Patients200714th CROIFebruary 25–28, 2007Los Angeles, CA Abst. 505
   Google Scholar
• Gayet-AgeronAAnanworanichJJupimaiTNo change in calculated creatinine clearance after tenofovir initiation among Thai patientsJ Antimicrob Chemother2007591034717376791
   PubMed Web of Science ®Google Scholar
• Gilead SciencesFull prescribing information, Truvada2006 Accessed September 25, 2006 at http://www.truvada.com/fpi.pdf
   Google Scholar
• GoicoecheaMLiuSBestBIncreased renal impairment in patients receiving TDF + PI vs TDF + NNRTI 14th CROI, Los Angeles, CA, February 25-28 20072007 Abst. 835
   Google Scholar
• HammerSMSaagMSSchechterMTreatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panelJAMA20062968274316905788
   PubMed Web of Science ®Google Scholar
• HaubrichRHRiddlerSDiRienzoGMetabolic Outcomes of ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial Treatment of HIV-1 Infection200714th CROILos Angeles Abst. 38
   Google Scholar
• HoetelmansRMMarienKDe PauwMPharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteersBr J Clin Pharmaco2007in press
   Web of Science ®Google Scholar
• IzzedineHHulotJSVillardEAssociation between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathyJ Infect Dis200619414819117083032
   PubMed Web of Science ®Google Scholar
• JamesCWSteinhausMCSzaboSTenofovir-related nephrotoxicity: case report and review of the literaturePharmacotherapy2004244151815040657
   PubMed Web of Science ®Google Scholar
• KarrerULedergerberBFurrerHDose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovirAIDS20051919879416260905
   PubMed Web of Science ®Google Scholar
• KiserJJCartenMLAquilanteCLThe effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patientsClin Pharmacol Ther2007In press
   Web of Science ®Google Scholar
• LacombeKBoellePYGozlanJHepatitis B virus plasma dynamics in HIV/HBV-co-infected patients: significant difference in the anti-viral activity of adefovir and tenofovir200714th Conference on Retroviruses and Opportunistic InfectionsFebruary 25–28Los Angeles Abstract 945 (poster)
   Google Scholar
• LawWPDoreGJDuncombeCJRisk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001AIDS2003172191914523276
   PubMed Web of Science ®Google Scholar
• LokASFMcMahonBChronic Hepatitis. AASLD Practice GuidelinesHepatology20074550739 Accessed 17 June 2007. URL: https://www.aasld.org/eweb/docs/chronichep_B.pdf17256718
   PubMedGoogle Scholar
• LouieMHoganCHurleyADetermining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individualsAIDS2003171151612819516
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKAReynoldsNAPloskerGLTenofovir disoproxil fumarate: a review of its use in the management of HIV infectionDrugs2005654133215669881
   PubMed Web of Science ®Google Scholar
• MocroftAKirkOGatellJChronic renal failure among HIV-1-infected patientsAIDS20072111192717502722
   PubMed Web of Science ®Google Scholar
• Martin-CarboneroLNúñezMGonzālez-LahozJIncidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapineHIV Clin Trials200341152012671779
   PubMed Web of Science ®Google Scholar
• MasquelierBBhaskaranKPillayDPrevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms; data from seroconverters in the CASCADE collaboration from 1987 to 2003J Acquir immunie Defic Syndr20054050511
   PubMed Web of Science ®Google Scholar
• MolinaJMFerchalFRancinanCOnce-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patientsJ Infect Dis200018259960210915095
   PubMed Web of Science ®Google Scholar
• MolinaJMJournotVMorand-JoubertLSimplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trialJ Infect Dis2005191830915717256
   PubMed Web of Science ®Google Scholar
• MulatoASCherringtonJMAnti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analysesAntiviral Res1997369179443665
   PubMed Web of Science ®Google Scholar
• Munoz de BenitoRMArribas LopezJRTenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backboneExpert Rev Anti Infect Ther200645233517009933
   PubMedGoogle Scholar
• MurphyMDO’HearnMChouSFatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosineClin Infect Dis2003361082512684925
   PubMed Web of Science ®Google Scholar
• NegredoEMoltoJMunoz-MorenoJASafety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approachAntivir Ther200493354215259896
   PubMed Web of Science ®Google Scholar
• NelsonMPortsmouthSStebbingJAn open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individualsAIDS200317F71012478090
   PubMed Web of Science ®Google Scholar
• PetersMGAndersenJLynchPRandomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127Hepatology20064411101617058225
   PubMed Web of Science ®Google Scholar
• PozniakALGallantJEDeJesusESuperior outcome for tenofovir DF, emtricitabine and efavirenz compared to fixed dose zidovudine/lamivudine and efavirenz in antiretroviral naïve patients2005Presented at the 3rd IAS Conference on Pathogenesis and TreatmentJuly 24–27Rio de Janeiro Abstract
   Google Scholar
• PozniakALGallantJEDeJesusETenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes – a 96-week analysisJ Acquir Immune Defic Syndr2006435354017057609
   PubMed Web of Science ®Google Scholar
• PruvostANegredoEBenechHMeasurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patientsAntimicrob Agents Chemother20054919071415855513
   PubMed Web of Science ®Google Scholar
• QiXXiongSYangHIn vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agentsAntivir Ther2007123556217591025
   PubMed Web of Science ®Google Scholar
• RistigMBCrippinJAbergJATenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-co-infected individuals for whom interferon-alpha and lamivudine therapy have failedJ Infect Dis20021861844712447773
   PubMed Web of Science ®Google Scholar
• RobbinsBLSrinivasRVKimCAnti-human immunodeficiency virus activity and cellular metabolism of a potential produrg of the acyclic nucleoside phosphonate 9-R-(2- phoxyosphonomethoxy-propyl) adeline (PMPA), Bis (isopropyloxymethylcarbonyl)PMPAAntimicrob Agents Chemother199842612179517941
   PubMed Web of Science ®Google Scholar
• RossLLimMLLiaoQPrevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States citiesHIV Clinical Trial2007818
   PubMed Web of Science ®Google Scholar
• SaagMSCahnPRaffiFEfficacy and safety of emtricitabine vs. stavudine in combination therapy in antiretroviral-naive patients: a randomized trialJAMA2004292180915249567
   PubMed Web of Science ®Google Scholar
• SaxPEGallantJEKlotmanPERenal safety of tenofovir disoproxil fumarateAIDS Read20071790–299104C3
   Google Scholar
• SchinaziRFMcMillanACannonDSelective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosineAntimicrob Agents Chemother1992362423311283296
   PubMed Web of Science ®Google Scholar
• SchaafBAriesSPKrammeEAcute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndromeClin Infect Dis200337e41312884188
   PubMed Web of Science ®Google Scholar
• SheppDHCurtisSRooneyJFCauses and consequences of hypokalemia in patients on tenofovir disoproxil fumarateAIDS20072114798117589195
   PubMed Web of Science ®Google Scholar
• SpenglerULichterfeldMRockstrohJKAntiretroviral drug toxicity – a challenge for the hepatologist?J Hepatol2002362839411830343
   PubMed Web of Science ®Google Scholar
• SquiresKPozniakALPieroneGJrTenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trialAnn Intern Med20031393132012965939
   PubMed Web of Science ®Google Scholar
• TortiCLapadulaGBarreiroPCD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral loadJ Antimicrob Chemother2007591141717434879
   PubMed Web of Science ®Google Scholar
• UwaiYIdaHTsujiYRenal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2)Pharm Res200748111517372702
   PubMed Web of Science ®Google Scholar
• Viread package insert Accessed 1 September 2006. URL: http://www.hivandhepatitis.com/hiv_and_aids/viread2005.pdf
   Google Scholar
• Van RompayKKJohnsonJABlackwoodEJSequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infectionRetrovirology200742517417971
   PubMed Web of Science ®Google Scholar